Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?


Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
04 2019
Historique:
received: 26 12 2018
revised: 20 02 2019
accepted: 25 02 2019
entrez: 20 3 2019
pubmed: 20 3 2019
medline: 7 3 2020
Statut: ppublish

Résumé

To estimate the number of past and future lung cancer deaths that have already been averted by tobacco control initiatives in Australia, and to estimate the number of additional deaths averted under various smoking scenarios. We predicted lung cancer mortality rates and case numbers to 2100 using a previously validated generalized linear model based on age, birth cohort and population cigarette smoking exposure. We estimated the impact of various tobacco control scenarios: 'actual tobacco control' (incorporating the aggregate effect of past and current taxation, plain packaging, mass media campaigns and other initiatives) and scenarios where 10%, 5% and 0% smoking prevalence was achieved by 2025, all of which were compared to a counterfactual scenario with the highest historical smoking consumption level continuing into the future as if no tobacco control initiatives had been implemented. Without tobacco control, there would have been an estimated 392,116 lung cancer deaths over the period 1956-2015; of these 20% (78,925 deaths; 75,839 males, 3086 females) have been averted due to tobacco control. However, if past and current measures continue to have the expected effect, an estimated 1.9 million deaths (1,579,515 males, 320,856 females; 67% of future lung cancer deaths) will be averted in 2016-2100. If smoking prevalence is reduced to 10%, 5% or 0% by 2025, an additional 97,432, 208,714 or 360,557 deaths could be averted from 2016 to 2100, respectively. Tobacco control in Australia has had a dramatic impact on the number of people dying from lung cancer. Several hundred thousand more lung cancer deaths could be averted over the course of the century if close-to-zero smoking prevalence could be achieved in the next decade.

Identifiants

pubmed: 30885346
pii: S0169-5002(19)30344-7
doi: 10.1016/j.lungcan.2019.02.028
pii:
doi:

Types de publication

Historical Article Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

208-215

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Qingwei Luo (Q)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia; The University of Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Electronic address: qingweil@nswcc.org.au.

Julia Steinberg (J)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia. Electronic address: julia.steinberg@nswcc.org.au.

Dianne L O'Connell (DL)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia; The University of Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia. Electronic address: dianneo@nswcc.org.au.

Xue Qin Yu (XQ)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia; The University of Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Electronic address: xueqiny@nswcc.org.au.

Michael Caruana (M)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia. Electronic address: michael.caruana@nswcc.org.au.

Stephen Wade (S)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia. Electronic address: stephen.wade@nswcc.org.au.

Francesca Pesola (F)

Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, Innovation Hub, Guys Cancer Centre, Guys Hospital, King's College London, London, UK. Electronic address: francesca.pesola@kcl.ac.uk.

Paul B Grogan (PB)

The University of Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Cancer Council Australia, Sydney, New South Wales, Australia. Electronic address: paul.grogan@cancer.org.au.

Anita Dessaix (A)

Cancer Prevention and Advocacy, Cancer Council NSW, Sydney, New South Wales, Australia. Electronic address: anita.dessaix@nswcc.org.au.

Becky Freeman (B)

The University of Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Electronic address: becky.freeman@sydney.edu.au.

Sally Dunlop (S)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia. Electronic address: sally.dunlop@nswcc.org.au.

Peter Sasieni (P)

Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, Innovation Hub, Guys Cancer Centre, Guys Hospital, King's College London, London, UK; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Electronic address: peter.sasieni@kcl.ac.uk.

Tony Blakely (T)

Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: ablakely@unimelb.edu.au.

Emily Banks (E)

National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australian Capital Territory, Australia. Electronic address: emily.banks@anu.edu.au.

Karen Canfell (K)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia; The University of Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Electronic address: karen.canfell@nswcc.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH